| Literature DB >> 27210076 |
Haq Nawaz1, Muhammad Aslam Shad, Mohammad Saeed Iqbal.
Abstract
Induction of hyperbilirubinemia in experimental rabbits by phenylhydrazine was optimized in terms of dose, dose interval and number of doses using response surface methodology. Central Composite Design was employed using five levels for each of the three input variables. Degree of hyperbilirubinemia was measured in terms of bilirubin level in serum of animals. A dose dependent significant elevation (P<0.05) of total serum bilirubin level was observed which was optimized by using eight factorial, six axial and six central points as suggested by experimental design. Optimum levels of phenylhydrazine dose, total number of doses and a dose interval to achieve maximum elevation (4.06 mg/dl-1) of total serum bilirubin were found to be 11.56 mg/kg-1 body weight, 8 and 24.65 h, respectively. The induction procedure was validated by performing five replicate experiments on a group of five animals which showed 3.56 ± 0.47 mg/kg-1 body weight elevation in total serum bilirubin level.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27210076 PMCID: PMC5111839 DOI: 10.1538/expanim.16-0011
Source DB: PubMed Journal: Exp Anim ISSN: 0007-5124
Preliminary selection of maximum tolerable dose of PH for experimental animals
| Animal groups | Dose (mg/kg-1 bw) | Dose interval (h) | Total number of doses (n) | Total dose (mg/kg-1 bw) | Total duration of treatment (h) | Physical signs | Tolerance by animals |
|---|---|---|---|---|---|---|---|
| 1 | 5 | 12 | 2 | 10 | 24 | No physical change | Survived |
| 5 | 12 | 4 | 20 | 48 | Slight appearance of yellow color of skin and eyes | Survived | |
| 5 | 12 | 8 | 40 | 96 | Slight change in skin and eye color | Survived | |
| 2 | 5 | 24 | 2 | 10 | 48 | No physical change | Survived |
| 5 | 24 | 4 | 20 | 96 | Slight appearance of yellow color of skin and eyes | Survived | |
| 5 | 24 | 8 | 40 | 192 | Slight appearance of yellow color of skin and eyes | Survived | |
| 3 | 5 | 48 | 2 | 10 | 96 | No physical change | Survived |
| 5 | 48 | 4 | 20 | 192 | No physical change | Survived | |
| 5 | 48 | 8 | 40 | 382 | Slight appearance of yellow color of skin and eyes | Survived | |
| 4 | 25 | 12 | 2 | 50 | 24 | Appearance of deep yellow color of skin and eyes | Survived |
| 25 | 12 | 4 | 100 | 48 | Anemic and lethargic response, gray color of skin and eyes due to excess hemolysis | Survived | |
| 25 | 12 | 8 | 200 | 96 | Swear anemic response, dark gray color of skin and eyes due to almost complete hemolysis | Died after 8th dose | |
| 5 | 25 | 24 | 2 | 50 | 48 | Appearance of deep yellow color of skin and eyes | Survived |
| 25 | 24 | 4 | 100 | 96 | Appearance of deep yellow color of skin and eyes | Survived | |
| 25 | 24 | 8 | 200 | 192 | Anemic and lethargic response, gray color of skin and eyes due to excess hemolysis | Survived | |
| 6 | 25 | 48 | 2 | 50 | 96 | No physical change | Survived |
| 25 | 48 | 4 | 100 | 192 | Appearance of deep yellow color of skin and eyes | Survived | |
| 25 | 48 | 8 | 200 | 382 | Anemic and lethargic response, gray color of skin and eyes due to excess hemolysis | Survived | |
| 7 | 50 | 12 | 2 | 100 | 24 | Anemic and lethargic response, gray color of skin and eyes due to excess hemolysis | Survived |
| 50 | 12 | 4 | 200 | 48 | Swear anemic response, dark gray color of skin and eyes due to almost complete hemolysis | Died after 4th dose | |
| 50 | 12 | 8 | 400 | Not treated | |||
| 8 | 50 | 24 | 2 | 100 | 48 | Anemic and lethargic response, gray color of skin and eyes due to excess hemolysis | Survived |
| 50 | 24 | 4 | 200 | 96 | Anemic and lethargic response, gray color of skin and eyes due to excess hemolysis | Survived | |
| 50 | 24 | 8 | 400 | 192 | Swear anemic response, dark gray color of skin and eyes due to almost complete hemolysis | Died after 7th dose | |
| 9 | 50 | 48 | 2 | 100 | 96 | Appearance of deep yellow color of skin and eyes | Survived |
| 50 | 48 | 4 | 200 | 192 | Anemic and lethargic response, gray color of skin and eyes due to excess hemolysis | Survived | |
| 50 | 48 | 8 | 400 | 382 | Swear anemic response, dark gray color of skin and eyes due to almost complete hemolysis | Died after 8th dose | |
Coded and actual levels of independent variables as per design by central composite design
| Standards | Experimental runs | Coded levels of variables | Actual levels of variables | |||||
|---|---|---|---|---|---|---|---|---|
| ξ1: Dose of PH (mg/kg-1 bw) | ξ2: Total number of doses (n) | ξ3: Dose interval (h) | ||||||
| 1 | 10 | –1 | –1 | –1 | 10 | 4 | 24 | |
| 2 | 1 | 1 | –1 | –1 | 20 | 4 | 24 | |
| 3 | 17 | –1 | 1 | –1 | 10 | 8 | 24 | |
| 4 | 20 | 1 | 1 | –1 | 20 | 8 | 24 | |
| 5 | 14 | –1 | –1 | 1 | 10 | 4 | 48 | |
| 6 | 12 | 1 | –1 | 1 | 20 | 4 | 48 | |
| 7 | 9 | –1 | 1 | 1 | 10 | 8 | 48 | |
| 8 | 8 | 1 | 1 | 1 | 20 | 8 | 48 | |
| 9 | 2 | –2 | 0 | 0 | 5 | 6 | 36 | |
| 10 | 3 | 2 | 0 | 0 | 25 | 6 | 36 | |
| 11 | 6 | 0 | –2 | 0 | 15 | 2 | 36 | |
| 12 | 18 | 0 | 2 | 0 | 15 | 10 | 36 | |
| 13 | 4 | 0 | 0 | –2 | 15 | 6 | 12 | |
| 14 | 15 | 0 | 0 | 2 | 15 | 6 | 60 | |
| 15* | 5 | 0 | 0 | 0 | 15 | 6 | 36 | |
| 16* | 16 | 0 | 0 | 0 | 15 | 6 | 36 | |
| 17* | 19 | 0 | 0 | 0 | 15 | 6 | 36 | |
| 18* | 13 | 0 | 0 | 0 | 15 | 6 | 36 | |
| 19* | 11 | 0 | 0 | 0 | 15 | 6 | 36 | |
| 20* | 7 | 0 | 0 | 0 | 15 | 6 | 36 | |
| Coded level of variables | –2 | –1 | 0 | 1 | 2 | |||
| Actual levels of variables | ||||||||
| ξ1: Dose of PH (mg/kg-1 bw) | 5 | 10 | 15 | 20 | 25 | |||
| ξ2: Total number of doses | 2 | 4 | 6 | 8 | 10 | |||
| ξ3: Dose Interval (h) | 12 | 24 | 36 | 48 | 60 | |||
*Center points.
Fig. 1.Dose dependent response of (a) Total serum bilirubin (TSB) and direct bilirubin (DB) level, and (b) Erythrocyte count and hemoglobin level of phenylhydrazine treated animals.
Experimental values of serum total bilirubin (STB) before and after treatment with PH at various levels of independent variables as per design by CCD
| Standards | Experimental runs | Actual levels of variables | STB (mg/dl-1) | |||||
|---|---|---|---|---|---|---|---|---|
| ξ1: Dose of PH (mg/kg-1 bw) | ξ2: Total number of doses | ξ3: Dose interval (h) | Control | PH treated | Elevation | |||
| 1 | 10 | 10 | 4 | 24 | 0.21 | 1.99 | 1.78 | |
| 2 | 1 | 20 | 4 | 24 | 0.33 | 3.32 | 2.99 | |
| 3 | 17 | 10 | 8 | 24 | 0.39 | 4.84 | 4.45 | |
| 4 | 20 | 20 | 8 | 24 | 0.37 | 5.2 | 4.83 | |
| 5 | 14 | 10 | 4 | 48 | 0.3 | 2.97 | 2.67 | |
| 6 | 12 | 20 | 4 | 48 | 0.3 | 3.21 | 2.91 | |
| 7 | 9 | 10 | 8 | 48 | 0.24 | 3.37 | 3.13 | |
| 8 | 8 | 20 | 8 | 48 | 0.31 | 4.22 | 3.91 | |
| 9 | 2 | 5 | 6 | 36 | 0.25 | 2.11 | 1.86 | |
| 10 | 3 | 25 | 6 | 36 | 0.29 | 5.19 | 4.9 | |
| 11 | 6 | 15 | 2 | 36 | 0.31 | 2.21 | 1.9 | |
| 12 | 18 | 15 | 10 | 36 | 0.21 | 3.31 | 3.1 | |
| 13 | 4 | 15 | 6 | 12 | 0.3 | 3.6 | 3.3 | |
| 14 | 15 | 15 | 6 | 60 | 0.38 | 3.41 | 3.03 | |
| 15 | 5 | 15 | 6 | 36 | 0.29 | 4.24 | 3.95 | |
| 16 | 16 | 15 | 6 | 36 | 0.25 | 3.98 | 3.73 | |
| 17 | 19 | 15 | 6 | 36 | 0.35 | 4.84 | 4.49 | |
| 18 | 13 | 15 | 6 | 36 | 0.32 | 4.93 | 4.61 | |
| 19 | 11 | 15 | 6 | 36 | 0.3 | 4.36 | 4.06 | |
| 20 | 7 | 15 | 6 | 36 | 0.31 | 4.65 | 4.34 | |
ANOVA in total serum bilirubin (TSB) in response to three variables by use of quadratic model
| Source | Sum of squares | df | Mean square | ||
|---|---|---|---|---|---|
| β0: Model | 15.94 | 9 | 1.77 | 7.35 | 0.0022 |
| β1: PH Dose | 4.73 | 1 | 4.73 | 19.65 | 0.0013 |
| β2: No. of doses | 4.38 | 1 | 4.38 | 18.18 | 0.0017 |
| β3: Dose interval | 0.24 | 1 | 0.24 | 1.01 | 0.3396 |
| β12 | 0.011 | 1 | 0.011 | 0.045 | 0.8369 |
| β13 | 0.04 | 1 | 0.04 | 0.17 | 0.6917 |
| β23 | 1.16 | 1 | 1.16 | 4.81 | 0.0531 |
| β11 | 1.02 | 1 | 1.02 | 4.24 | 0.0666 |
| β22 | 4.48 | 1 | 4.48 | 18.59 | 0.0015 |
| β33 | 1.64 | 1 | 1.64 | 6.82 | 0.026 |
| Residual | 2.41 | 10 | 0.24 | ||
| Lack of Fit | 1.84 | 5 | 0.37 | 3.21 | 0.1134 |
| Pure Error | 0.57 | 5 | 0.11 | ||
| Cor Total | 18.35 | 19 | |||
| CV | 14.3 | ||||
| R2 | 0.8687 | ||||
| Adjusted R2 | 0.7506 | ||||
| Predicted R2 | 0.1355 | ||||
| Adequate precision | 9.97 |
Fig. 2.3D response surface plots of elevation in total serum bilirubin level (a-c) in response to variation in phenylhydrazine dose, total number of doses and dose interval.
Fig. 3.Correlation between the experimental and predicted values of total serum bilirubin levels (mg/dl−1) at selected levels of phenylhydrazine dose, number of doses and dose interval.
Optimum levels of independent variables where the desired level of the response variables is predicted to be achieved
| Variables | Goal | Lower limit | Upper limit | Optimum levels | Desirability | |||
|---|---|---|---|---|---|---|---|---|
| X1 | X2 | X3 | Y | |||||
| Dose of PH (mg/kg-1 bw) | minimize | 5 | 25 | |||||
| Total number of doses (n) | in range | 2 | 10 | |||||
| Dose interval (h) | in range | 12 | 60 | |||||
| Elevation in total serum bilirubin (mg/dl-1) | maximize | 1.78 | 4.9 | 11.56 | 8 | 24.56 | 4.06 | 0.7 |
| Reproducibility | ||||||||
| Elevation in total serum bilirubin (mg/dl-1) | 3.58 ± 0.47 | |||||||